Merck & Company Inc.

Pharmaceutical industry

Rosetta Biosoftware's Rosetta Resolver System to Enhance Gene Expression Data Management and Analysis for CDER's Voluntary Genomics Data Submissions Program

The US Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) has announced that it will be evaluating the Rosetta Resolver system from Rosetta Biosoftware for its use in the Voluntary Genomics Data Submissions (VGDS) program. The Rosetta Resolver system will be used to manage

Pharmaceutical industry

Vioxx Verdict to Set Tone for 4,000+ Wrongful Death and Injury Cases Against Merck

In Angleton, Texas, jurors will hear closing arguments in the first Vioxx-related case to go to trial, a significant development in the face of 4,000+ wrongful-death and injury cases against Merck. The case involves a 59-year-old man who died of an irregular heartbeat after taking Vioxx for eight months.

Pharmaceutical industry

Geron Corp. and Merck Collaborate to Develop Telomerase Cancer Vaccine

Geron Corp., a leader in the development of telomerase-based cancer therapies, has entered into a collaboration and license agreement with pharmaceutical giant Merck & Co. to develop a cancer vaccine targeting telomerase. This strategic alliance combines Geron's expertise in telomerase biology with Merck's expertise in vaccine

Pharmaceutical industry

Vioxx Lawsuit Opens in Texas, Spotlighting a Billion-Dollar Liability for Merck

As the trial of the first Vioxx lawsuit against Merck unfolds in Angleton, Texas, the case has piqued the interest of analysts and the public alike. The lawsuit aims to prove that Merck's painkiller Vioxx, which was voluntarily withdrawn from the market in 2004, doubled the risk of

Pharmaceutical industry

Vioxx Trial Exposes Hidden Risks: A Catalyst for Change in Pharmaceutical Research

Renée Montagne and Snigdha Prakash report on the first trial of a wrongful death case against Merck, drugmaker of Vioxx, a painkiller pulled from the market in 2004 due to cardiovascular risks. The plaintiffs will argue that Merck knew about the risks but hid them from doctors and patients. The

United States. Food and Drug Administration

FDA Panel Rules on Safety of Cox-2 Inhibitor Pain Drugs

A US regulatory panel has ruled that pain drugs Celebrex and Bextra, made by Pfizer, and Vioxx, made by Merck, can remain on the market with strong warnings about increased heart and stroke risk. The decision was made by the Food and Drug Administration (FDA) advisory panel after a three-day

United States. Food and Drug Administration

Cox-2 Inhibitors Under Scrutiny: EU and US Regulators Examine Safety Risks

As the world's largest drug manufacturers prepare for a tense week of regulatory scrutiny, the future of a widely used class of anti-inflammatory drugs, cox-2 inhibitors, hangs in the balance. The European Medicines Agency and the US Food and Drug Administration are set to deliver verdicts that could